Home Tools
Log in
Cart

Search Result

Search Results for " 22rv1 "

15

Compounds

Cat No. Product Name Synonyms Targets
T36841 IPI-9119 Fatty Acid Synthase
IPI-9119 is an orally active, selective and irreversible FASN inhibitor (IC50 = 0.3 nM).
T9005 VPC-80051 racemate Others
VPC-80051 is the first small molecule inhibitor of hnRNP A1 splicing activity by using a computer-aided drug discovery approach.
T78989 BET-IN-16 Epigenetic Reader Domain
BET-IN-16 (Comp I), a bromodomain and extra-terminal (BET) inhibitor, demonstrates anticancer activity by impeding the growth of prostate cancer cells. It exhibits potent inhibitory effects with half-maximal inhibitory c...
T78837 CP-07 CDK
CP-07 is a selective and effective PROTAC CDK9 degrader (DC50: 43 nM), demonstrating inhibition of 22RV1 cell proliferation (IC50: 62 nM) and colony formation by attenuating levels of Mcl-1 and c-Myc. Additionally, CP-07...
T61327 BRD4 Inhibitor-15
BRD4 Inhibitor-15 (compound 13) is a highly potent and specific inhibitor of BRD4, effectively inhibiting it with an IC50 of 18 nM. By regulating the Bcl-2/Bax proteins and activating the caspase-3 signaling pathway, BRD...
T63109 Y08284
Y08284 is a selective, potent, orally active inhibitor of CBP bromodomain (IC50: 4.21 nM). y08284 inhibits the proliferation of the prostate cancer cell lines LNCaP, C4-2B and 22Rv1 and has anti-tumour effects.
T13552 ARD-266 Others
ARD-266 is a highly potent and VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. ARD-266 effectively induces the degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines (DC50s...
T15205 EL-102 EL102 Microtubule Associated , HIF
EL-102 is a HIF1α inhibitor with anticancer activity that inhibits microtubule protein polymerization and can be used to study prostate cancer.
T13958 VHL Ligand 8 Others
VHL Ligand 8, a VHL ligand essential for synthesizing ARD-266, acts as a highly potent VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. It efficiently facilitates the degradation of AR protein in AR-positive p...
T78945 WCA-814 Androgen Receptor
WCA-814, an androgen receptor (AR) antagonist-Hsp90 inhibitor conjugate, induces degradation of both full-length and AR-V7, exhibiting cytotoxic effects in prostatic cancer cells with half maximal inhibitory concentratio...
T17689 Boc-Pip-alkyne-Ph-COOH Others
Boc-Pip-alkyne-Ph-COOH, a PROTAC linker characterized by its alkyl/ether composition, plays a crucial role in synthesizing PROTACs including ARD-266. This compound demonstrates significant efficacy in promoting the degra...
T74410 PROTAC AR-V7 degrader-1
PROTAC AR-V7 degrader-1 (Compound 6) is an orally bioavailable, potent, and selective degrader targeting the androgen receptor (AR) variant V7, achieving degradation with a DC50 of 0.32 µM by directing the VHL E3 ligase ...
T83853 L-K6L9 TFA
L-K6L9, a cytolytic peptide comprised of L-isomer leucine and lysine, demonstrates cytotoxicity against both androgen-independent (LNCaP-CL1) and androgen-dependent (22Rv1 and LNCaP) human prostate cancer cells, with LC5...
T83936 LL-K9-3
LL-K9-3, a selective hydrophobic tagging technology (HyT)-based degrader, specifically targets the CDK9-cyclin T1 complex, displaying DC50 values of 589 nM for cyclin T1 and 662 nM for CDK9. This compound consists of the...
T30123 ARD-69
ARD-69 is a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. ARD-69 induces degradation of AR protein in AR-positive prostate cancer cell lines...
TargetMol